Streetbeat News

ADIL

Adial Pharmaceuticals, Inc.

https://www.adialpharma.com

Industry

Biotechnology

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Open

1.15

Mkt cap

6.8M

Volume

270K

High

1.15

P/E Ratio

-0.27

52-wk high

4.17

Low

1.04

Div yield

N/A

52-wk low

0.77

Adial Pharmaceuticals announced the completion of the last patient dose in its pharmacokinetics study of AD04, a treatment for Alcohol Use Disorder.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 12:30 pm

Adial Pharmaceuticals shares are trading higher following the company's announcement of a new patent application for AD04.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 1:14 pm

Adial Pharmaceuticals has filed a new patent application for AD04, its lead investigational treatment for alcohol use disorder in heavy drinking patients. The patent is expected to protect core assets through at least 2044.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 12:33 pm

U.S. stocks traded slightly higher with the Dow Jones gaining over 50 points. Coca-Cola reported strong Q2 results and raised its FY24 forecast. Azitra, Adial Pharmaceuticals, and Frequency Electronics saw significant stock price increases, while Jaguar Health, TransCode Therapeutics, and Cellectar Biosciences experienced sharp declines.

Portfolio Pulse from Avi Kapoor

July 23, 2024 | 6:32 pm

Comcast Corporation (NASDAQ:CMCSA) shares fell 6.1% after reporting worse-than-expected Q2 sales results. Other notable stock movements include Azitra, Inc. (NYSE:AZTR) jumping 529% due to a new patent, and Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) rising 148% after advancing a study. General Motors Company (NYSE:GM) fell 6.1% after delaying EV projects.

Portfolio Pulse from Avi Kapoor

July 23, 2024 | 5:21 pm

U.S. stocks traded higher with the Nasdaq Composite gaining over 100 points. GE Aerospace reported better-than-expected Q2 earnings and raised its FY24 outlook. Azitra, Adial Pharmaceuticals, and Frequency Electronics saw significant stock price increases, while Jaguar Health, TransCode Therapeutics, and Cellectar Biosciences experienced sharp declines.

Portfolio Pulse from Avi Kapoor

July 23, 2024 | 4:03 pm

US stocks edged higher with the Nasdaq Composite gaining 0.2%. General Motors reported better-than-expected Q2 earnings and raised its guidance. Azitra, Adial Pharmaceuticals, and Agape ATP saw significant stock price increases, while Jaguar Health, TransCode Therapeutics, and Exicure experienced sharp declines.

Portfolio Pulse from Avi Kapoor

July 23, 2024 | 2:15 pm

Adial Pharmaceuticals shares are trading higher after the company announced it advanced into the second cohort and commenced dosing for the Pharmacokinetics Study of AD04 for alcohol use disorder.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 12:50 pm

Milestone Scientific announced a new price assignment for its products in two Medicare regions: Jurisdiction L (JL) and Jurisdiction H (JH).

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 12:15 pm

Adial Pharmaceuticals (NASDAQ:ADIL) has advanced to the second cohort in its pharmacokinetics study of AD04, a treatment for Alcohol Use Disorder. The study, which began in June 2024, is expected to conclude in Q4 2024, with topline results anticipated in the same quarter. The results will inform the design of a Phase 3 Clinical Trial.

Portfolio Pulse from Vandana Singh

July 23, 2024 | 12:00 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.